Musa Kolapo Oladejo

Mr. Musa Kolapo Oladejo

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2026 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
Kamoru ADEDOKUNKamoru ADEDOKUN
Kamoru ADEDOKUN
ABAminah Bello
Aminah Bello
GOGbadebo M Oyeniyi
Gbadebo M Oyeniyi
MOMusa Kolapo Oladejo
Musa Kolapo Oladejo
TATajudeen A Adebisi
Tajudeen A Adebisi
Exosomes, the nanoscale extracellular vesicles released by most cell types, are increasingly recognized as potent regulators of immune communication. This review provides a mechanistic and integrative perspective on the immunological functions of exosomes, highlighting their roles in both immune stimulation and suppression across physiological and pathological contexts. We begin by dissecting the molecular architecture of exosomes—focusing on immunologically active components such as ESCRT proteins, tetraspanins, RabGTPases, and lipid mediators—and explore how these elements contribute to exosome biogenesis and immune function. The review further examines exosomal cargo enriched in pattern recognition receptor (PRR) ligands, including damage-associated molecular patterns (DAMPs), pathogen-associated molecular patterns (PAMPs), and microRNAs, and discusses how these molecules activate toll-like receptors and other PRRs to orchestrate innate immune responses through endosomal and cytosolic signaling cascades. Special emphasis is given to MHC-mediated antigen presentation via exosomes, distinguishing classical and non-canonical pathways and their interplay with downstream immune signaling mechanisms. We present a dichotomous view of exosomes as both immunostimulatory and immunosuppressive agents, detailing their roles in T-cell cross-priming, dendritic cell maturation, tumor progression, and metastasis. Moreover, we review pathogen-driven hijacking of exosomal pathways and their implications for immune evasion. Finally, we discuss the therapeutic promise of exosomes in cancer immunotherapy and vaccine design, advocating for their strategic integration into next-generation immunomodulatory approaches.

23 August 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SASaheed Olaide Anifowose
Saheed Olaide Anifowose
Abdalrahaman M SalihAbdalrahaman M Salih
Abdalrahaman M Salih
MOMusa Kolapo Oladejo
Musa Kolapo Oladejo
ARAhmed Rady
Ahmed Rady
MAMobarak AlMosallam
Mobarak AlMosallam
BABadr A. Al-Dahmash
Badr A. Al-Dahmash
Background/Objectives: Aristolochia ringens, a medicinal plant widely used in traditional medicine, has shown potential therapeutic applications. This study aimed to investigate the anticancer mechanism of action of its crude extract against human colorectal adenocarcinoma cells (Caco-2 and HT-29). Methods: Cell viability was assessed using the MTT assay to determine IC50 values. Immunofluorescence microscopy was used to examine nuclear morphology and microtubule integrity. Flow cytometry with PI staining was used for cell cycle analysis and Annexin V-FITC/PI staining for apoptosis detection. Mitochondrial membrane potential was evaluated using JC-1 dye. Bioactivity-guided fractionation was performed via HPLC, and GC–MS was used to profile active constituents. Results: The extract exhibited dose-dependent cytotoxicity with IC50 values below 30 µg/mL in colon adenocarcinoma cell lines. Treated Caco-2 cells showed nuclear shrinkage and disrupted microtubules. PI-based flow cytometry revealed G1 phase arrest, and Annexin V-FITC/PI staining indicated enhanced late apoptosis. JC-1 staining demonstrated mitochondrial depolarization. HPLC fractionation identified fractions 2 and 3 as active, and preliminary GC–MS analysis tentatively annotated the presence of alkaloids, sesquiterpenes/diterpenes, and steroidal compounds. Conclusions: A. ringens exerts anticancer effects through a mitochondria-mediated apoptotic pathway, involving G1 checkpoint arrest and cytoskeletal disruption. These findings provide the first integrated cellular and mechanistic evidence of its anticancer potential in colorectal cancer, supporting its promise as a source of novel therapeutic lead compounds.

19 May 2026 in Next Materials
Verified
Journal Article
Open access
KAKamoru A. Adedokun
Kamoru A. Adedokun
HFHassanat T. Fayemo
Hassanat T. Fayemo
GOGbadebo Maroof Oyeniyi
Gbadebo Maroof Oyeniyi
ABAminah Bello
Aminah Bello
OOOluwaseun Adenike Orugun
Oluwaseun Adenike Orugun
PAPelumi Daniel Adewole
Pelumi Daniel Adewole
Modern drug discovery is undergoing a transformative shift driven by the integration of molecular, cellular, genomic, and immunological approaches. This review provides a comprehensive overview of cutting-edge methodologies that are reshaping target identification and therapeutic development, including multi-omics profiling, CRISPR–Cas functional genomics, high-throughput sequencing, and bioinformatics-driven network analysis. We highlight how these approaches enable precise dissection of disease-relevant biological mechanisms, facilitate validation of drug targets, and improve experimental efficiency in both in vitro and in vivo systems. Beyond discovery, we emphasize translational applications, illustrating the clinical potential of CRISPR/Cas9 in cancer therapy and lessons learned from rare and complex diseases such as sickle cell disease, transfusion-dependent beta-thalassemia, and Alzheimer’s disease. Additionally, the review explores advances in therapeutic antibodies, engineered biologics, and antibody–drug conjugates, detailing experimental strategies for their design, optimization, and mechanistic evaluation. By integrating experimental innovation with computa­tional modeling, this work bridges fundamental molecular insights with clinical relevance, providing a frame­work for rational drug development. Designed as both an educational resource for newcomers and a practical guide for experienced researchers, the review emphasizes mechanistically grounded, clinically translatable strategies that accelerate modern drug discovery and precision medicine, offering a forward-looking perspective on the integration of emerging technologies into next-generation therapeutics.